Kjetil TASKÉN et al



RECEIVED

6/15


SEP 0 6 2002

TECH CENTER 1600/2900

RECEIVED

SEP 0 9 2002







SEP 0 6 2002


TECH CENTER 1600/2900

Fig. 4B

7/15

RECEIVED

SEP **0 9** 2002



Kjetil TASKÉN et al USE OF INNUNOMODULATING USSN 09/428,458 **RECEIVED** SEP 0 9 2002 **TECH CENTER 1600/2900** SEP 0 6 2002 9/15 TECH CENTER 1600/2900 125 250 500 1000 83 83 9 ∞ 63 125 250 500 1000 63 125 125 125 125 125 125 125 125 125 AGONIST ± ANTAGONIST 83 9 ∞ 33 9 ∞ **—00006** -00009 30000 Rp-8-Br-cAMPS Sp-8-Br-cAMPS $(10^{-6}M)$ 2 HJ-THYMIDINE INCORPORATION (cpm) / 75,000 CELLS




RECEIVED

SEP 0 6 2002

TECH CENTER 1600/2900

Fig. 6A

10/15





SEP 0 9 2002


TECH CENTER 1600/2900

11/15

RECEIVED

SEP 0 6 2002

Fig. 6B



(3H)-THYMIDINE INCORPORATION 100000 50000 -0 0.2 10³ 2 10³ 0.2 IL-2 (ng / mL) 2 10 50 10 50 10³ 10³ 10³ $Rp(\mu M)$






RECEIVED

SEP **0 9** 2002

13/15

Fig. 8






14/15

RECEIVED

SEP **0 9** 2002

Fig. 9



RECEIVED

SEP 0 9 2002

15/15

Fig. 10

